VivoSeq
Oncology

Esophageal Squamous Carcinoma

1

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Esophageal Squamous Carcinoma is an early-stage landscape with 1 program across 2 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., Shandong Luye Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sichuan Baili Pharmaceutical Co., Ltd.

1 program

Phase 2S

Shandong Luye Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

PD-1

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

6

clinical trials

Not yet recruiting2 · 33%
Unknown status2 · 33%
Active, not recruiting1 · 17%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06869213·30 enrolled
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
Active, not recruiting·SSun Yat-sen University·Phase 1·NCT06020885·18 enrolled
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07019181·26 enrolled
A Prospective, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitor Plus Platinum-Based Chemotherapy
Not yet recruiting·BBeijing GoBroad Hospital·Phase 2·NCT07688291·40 enrolled
Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma
Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 3·NCT01752205·120 enrolled
A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma
Unknown status·SShandong Luye Pharmaceutical Co., Ltd.·Phase 4·NCT00642239·48 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)